These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26497956)

  • 1. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
    Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
    BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary.
    Ho CM; Lee FK; Huang SH; Cheng WF
    Am J Cancer Res; 2018; 8(1):56-69. PubMed ID: 29416920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
    Ho CM; Huang CJ; Huang CY; Wu YY; Chang SF; Cheng WF
    Mol Cancer; 2012 Aug; 11():53. PubMed ID: 22871047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
    Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
    Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
    Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
    Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
    Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.
    Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X
    Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CACNA1H restrains chemotherapy resistance in ovarian clear cell carcinoma cells by repressing autophagy.
    Shi H; Zheng L; Jiang X; Chen H
    Mol Genet Genomics; 2024 Aug; 299(1):77. PubMed ID: 39105964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus combined with 5-aza-2-deoxycytidine generated potent anti-tumor effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway.
    Ho CM; Lee FK; Yen TL; Huang SH; Cheng WF
    Am J Cancer Res; 2022; 12(4):1686-1706. PubMed ID: 35530273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
    Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.
    Perez-Juarez CE; Arechavaleta-Velasco F; Zeferino-Toquero M; Alvarez-Arellano L; Estrada-Moscoso I; Diaz-Cueto L
    Med Oncol; 2019 Nov; 37(1):4. PubMed ID: 31713081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer.
    Yu Y; Yin D; Hoque MO; Cao B; Jia Y; Yang Y; Guo M
    Tumour Biol; 2012 Apr; 33(2):307-14. PubMed ID: 22095135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
    Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
    Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
    Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
    Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.